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establishing inflammation to promote ear-
lier steps in cancer progression of skin
previously “initiated” by the HPV16 trans-
genes. In contrast to the results of Daniel
et al., CD4+ cells were not required for this
early tumor promotion. The discrepancy
may relate to effects of different cells of
the adaptive immune system at different
stages of tumor development and pro-
gression. For Daniel et al., deficiency of
CD4 cells correlated with a trend toward
earlier lesions (hyperplasia versus dys-
plasia at 6 months) and a small but signif-
icant difference in incidence of squamous
cell tumors at a later stage of tumor pro-
gression (at 12 months).
The observations of de Visser et al.
raise a number of questions:
• Are antibodies mediating this tumor
promotion, or might B cell-derived
chemokines, cytokines, or other soluble
molecules?
• If the active principle is antibody,
what is the specificity? Cutaneous bacter-
ial symbionts or pathogens, autoantigens
(including the HPV transgene products),
or products of mutations in transformed
cells? Tantalizingly, de Visser et al. briefly
relate unpublished observations that early
development of tumors is not different in
germ-free mice, suggesting that bacteria
are not driving antibodies.
• If antibodies, what are the mecha-
nisms for eliciting inflammation (Figure 1)?
Signaling through activating Fc receptors
on myeloid cells to initiate production of
inflammatory molecules? Complement
activation producing the anaphylatoxins
C3a and C3b to drive inflammation
through complement receptors on myeloid
cells? Both?
• Do T cells play a role in the observa-
tions? Importantly, the authors could not
rule out the complete absence of T cells
in their adoptive transfer experiments.
If antibodies are found to be the
mediators of the inflammatory response
early on during carcinogenesis in this
model, the answers to these questions
will become relevant to developing strate-
gies for prevention of cutaneous epithelial
tumors and possibly other cancers.
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Pancreatic cancer likely reflects a model
type of cancer displaying essentially all
molecular and biological cancer hall-
marks, such as genetic and epigenetic
alterations, chromosomal instability, pro-
gression from preneoplastic lesions to
an invasive and metastatic phenotype,
and virtually complete resistance to any
therapeutics tested so far. Along with
this depressing clinical situation goes a
considerable insight into the genetic and
cellular events from the earliest preneo-
plastic lesions, found in as many as 50
percent of normal pancreata in the
elderly population (Hruban et al., 2004),
to late metastatic disease (Figures 1A
and 1B). Due to significant progress in
the development of genetically engi-
neered murine models of human can-
cers (Van Dyke and Jacks, 2002),
mouse models of pancreatic cancer
have evolved that mimic the human dis-
ease genetically and morphologically in
an astonishing way. By conditional acti-
vation of endogenously expressed
oncogenic KrasG12D in the pancreas of
mice, Hingorani, Tuveson, and col-
leagues were able to induce preneo-
plastic lesions that eventually progress
to invasive and metastatic pancreatic
adenocarcinoma (Hingorani et al., 2003
and Figure 1C). However, invasive and
metastatic cancer developed at a
considerable advanced age in mice,
revealing a rather slow progression con-
sidering that PanIN-3 lesions can
already be detected at the age of 4–6
months to the time of full-blown pancre-
atic cancer at around 12–15 months of
age. By introducing tissue-specific defi-
ciency of the Ink4a/Arf tumor suppres-
sors, often mutated or silenced in
Chromosomal instability in mouse metastatic pancreatic cancer—
it’s Kras and Tp53 after all
A human pancreatic cancer progression model from intraepithelial neoplasia to ductal adenocarcinoma has been pro-
posed. This process has been modeled in the mouse by activation of mutant Kras in pancreatic progenitor cells. In this
issue of Cancer Cell, Hingorani et al. (2005) present a modification of their initial model by introducing a mutant Tp53.This
combination of genetic alterations leads to rapid and increased frequency of neoplasia progression resulting in pancreat-
ic cancers that manifest chromosomal instability in the presence of apparent intact telomeres. These findings introduce
Tp53-mediated chromosomal instability as key event for carcinoma development in this mouse model.
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preneoplastic human lesions and
believed to be necessary for progres-
sion of PanIN lesions, into this model,
DePinho and colleagues noted an accel-
erated progression and lethal invasive
tumor burden at around three months of
age (Aguirre et al., 2003 and Figure 1C).
Interestingly, however, no mutations in
other genes often altered in human pan-
creatic cancer, and no macroscopic
metastases into other organs typically
invaded in human pancreatic cancer,
were detectable. In addition, these
tumors, despite their high local aggres-
siveness, showed a rather benign
cytogenetic profile. Thus, despite the
tremendous advances in mimicking the
human disease from early transgenic to
these highly elaborated models, some of
the key events in pancreatic carcinogen-
esis have not evolved so far. Besides the
development of metastatic tumor pheno-
types during the carcinogenic process,
chromosomal instability, another hall-
mark of human cancers, has been very
hard to recapitulate in the mouse. In fact,
although human epithelial carcinomas,
and especially pancreatic cancers, dis-
play a high degree of genomic instability,
murine models of all kinds of sponta-
neous cancers have shown a surprising-
ly bland cytogenetic profile. Since
chromosomal instability has been asso-
ciated with telomere dysfunction, and
because telomeres of mice are much
longer than human ones, differences in
telomere function and dynamics have
been considered to be one of the rea-
sons why spontaneous carcinomas are
relatively rare in mice, which more often
develop lymphomas and sarcomas
(Sharpless and DePinho, 2004).
Accordingly, mice with telomeric dys-
function in a p53+/− background indeed
show a shift in tumor spectrum toward
epithelial cancers (Artandi et al., 2000).
However, this view may be challenged
by a new report published in this issue of
Cancer Cell.
By introducing a point mutation in
the Tp53 tumor suppressor gene
(Tp53R172H) into the aforementioned
KrasG12D mouse, Hingorani et al. (2005)
now seem to have taken a further step in
recapitulating human pancreatic cancer.
In this model, a structural mutant
Tp53R172H is activated the same way as
oncogenic KrasG12D, leading to targeted
expression in pancreatic cells by using
PDX-1-Cre mice. Interestingly, concomi-
tant expression of endogenously con-
trolled KrasG12D and Tp53R172H led to an
invariant loss of the wild-type Tp53
allele and halved the time of progression
from preneoplastic PanIN lesions to full-
blown metastatic pancreatic cancer. In
contrast to the highly invasive local
tumors seen in mice with concomitant
KrasG12D expression and biallelic defi-
ciency of Ink4a/Arf, these mice devel-
oped macroscopic metastases to
organs also affected in the human dis-
ease. Somewhat surprisingly, however,
given the usually observable lack of
large-scale genetic alterations in murine
epithelial malignancy models, Hingorani
et al. (2005) also found induction of
widespread chromosomal instability
with aberrant chromosomal rearrange-
ments and nonreciprocal translocations.
Moreover, these alterations occurred in
the setting of apparently intact telom-
eres (Figure 1C).
An increasing amount of data points
to an important role of chromosomal
instability and aneuploidy in epithelial
carcinogenesis, possibly enabling can-
cer cells to accumulate mutations need-
ed for as different tasks as stromal
interaction, angiogenesis, extravasation,
and metastasis. While it is not clear in
what exact way chromosomal instability
may be essential for tumorigenesis, sev-
eral studies have reported its occurrence
early in tumor development and even in
preneoplastic lesions. How then might
chromosomal instability have arisen in
the mouse model presented by
Hingorani et al.? In contrast to the afore-
mentioned KrasG12D;Ink4a/Arf deficiency
model, in which biallelic loss of Ink4a/Arf
under continuous oncogenic KrasG12D
stimulus led to aggressive locally inva-
sive tumors, expression of Tp53R172H
results in loss of the wild-type Tp53
allele, possibly as a consequence of high
selection pressure against Tp53 after
KrasG12D-induced cellular stress.
Although the question which of these,
the initial alteration in Tp53 function or
the later loss of the wild-type allele, lead
to chromosomal instability has not been
formally addressed, mutation in Tp53
with subsequent acquisition of onco-
genic properties may likely be the driving
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Figure 1. Progression model of pancreatic
cancer
A: Histology of pancreatic intraepithelial
neoplasia (PanIN) in specimens of human
pancreas, which progress to pancreatic
ductal adenocarcinoma (PDAC).
B: Genetic alterations in microdissected
human PanIN lesions summarized to a genet-
ic progression model.
C: Modeling pancreatic cancer in the
mouse (KrasG12D, Hingorani et al., 2003;
KrasG12D;Tp53R172H, Hingorani et al., 2005,
KrasG12D;Ink4a/Arf−/−, Aguirre et al., 2003).
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force for chromosomal instability and
additional genetic alterations, including
LOH of wild-type Tp53, eventually lead-
ing to the observable highly metastatic
phenotype. In this scenario, chromoso-
mal instability might develop at a rather
early time point, as is suggested by
Hingorani et al., possibly in PanIN-3
lesions. As the appearance of chromoso-
mal instability is probably of diagnostic
and prognostic relevance, this question
certainly needs further investigation.
What, if any, role telomere function has
in this setting is far from being clear.
Interestingly, telomere dysfunction in this
model may not be required due to the
ability of mutated Tp53 together with
oncogenic KrasG12D to induce large-scale
genomic instability, a hypothesis chal-
lenging our understanding of the devel-
opment of epithelial cancers in man and
mice. Indeed, mice with targeted inser-
tion of structural or contact mutations in
the endogenous Tp53 gene reveal an
altered tumor spectrum with an
increased incidence of total malignan-
cies and notably of epithelial cancers
(Olive et al., 2004). Thus, missense
mutations in the Tp53 gene seem to
increase the oncogenic potential of cells,
also acknowledged by the fact that Tp53
is most often not deleted, but rather
altered, by missense mutation followed
by LOH in malignancy. Therefore, given
this new data from mice with endoge-
nously expressed mutated Tp53, it may
be fair to say that simply knocking out
Tp53 as done in multiple studies in the
past has been an oversimplification of
the complex Tp53 network. Compatible
with this hypothesis are data from the
Elastase-TGFalpha;Tp53+/− mouse, in
which a rather characteristic pattern of
genetic alterations, but not this degree of
chromosomal instability, was notable
(Wagner et al., 2001; Schreiner et al.,
2003). In the future, it will be of great
importance to identify pathways interact-
ing with mutant Tp53 as well as to find
therapeutic approaches for inhibiting its
oncogenic function. As missense muta-
tions in Tp53 seem to make the differ-
ence regarding the development of
genetic instability and evolution of
epithelial cancers, it is interesting to note
that the selection pressure for Tp53
mutations in mice does not seem to be
as high as in humans, an issue which
should enforce further investigations.
Interestingly, in PDX-1-Cre mice, acti-
vation of mutated KrasG12D and Tp53R172H
already occurs during embryogenesis.
However, and somewhat surprisingly,
pancreatic tumorigenesis seems to devel-
op only in the adult organ, with the very
first PanIN-1 lesions occurring not much
earlier than in KrasG12D mice without Tp53
mutation. Could this mean that control of
cell division in the embryonic pancreas is
more tightly controlled than in the adult
pancreas, thus preventing aberrant DNA
replication and conferring robust genomic
stability? Although not well studied, evolu-
tionary pressure has possibly led to
redundant systems preventing the occur-
rence of genomic instability during
embryogenesis.
Some questions remain un-
answered. Does the metastatic pheno-
type as seen in this mouse represent a
uniform genetic pathway occurring in
this specific genetic setting, or do the
metastases represent clonal events
with a variety of genetic events generat-
ing a similar phenotype? What genes
and signaling pathways are affected?
What effect may other mutated forms of
Tp53 elicit in this model, such as the
contact mutation Tp53R270H? Might we
see different biological behaviors by
altering missense mutations within the
Tp53 gene? Are the observable tumors
and metastases dependent on mutated
Tp53 function, and most importantly, is
genetic instability and the early devel-
opment of metastatic pancreatic cancer
reversible by knocking down mutated
Tp53? Is there a therapeutic window?
In summary, the introduction of con-
ditional point-mutated Tp53 has led to the
recapitulation of important and previously
undescribed features of human pancreat-
ic cancer in the mouse. Chromosomal
instability can now be appreciated as a
key event in the development of metasta-
tic carcinomas in the mouse, adding an
important new piece to the puzzle of this
nearly untreatable tumor.
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